
Did the FDA kill CoAxia using the new de novo process? Despite reducing mortality rates in patients 2 to 1 over standard of care, the FDA pushed CoAxia into the new de novo process. In retrospect, it also killed the company. Attorney Mark DuVal, is warning clients to beware the de novo process lest it devours you.